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Abstract: 
A Genomic Target Database (GTD) has been developed having putative genomic drug targets for human bacterial pathogens. The selected 
pathogens are either drug resistant or vaccines are yet to be developed against them. The drug targets have been identified using subtractive 
genomics approaches and these are subsequently classified into (1) Drug targets in pathogen specific unique metabolic pathways, (2) Drug targets 
in host-pathogen common metabolic pathways, and (3) Membrane localized drug targets. HTML code is used to link each target to its various 
properties and other available public resources. Essential resources and tools for subtractive genomic analysis, sub-cellular localization, vaccine 
and drug designing are also mentioned. To the best of authors knowledge, no such database (DB) is presently available that has listed metabolic 
pathways and membrane specific genomic drug targets based on subtractive genomics. Listed targets in GTD are readily available resource in 
developing drug and vaccine against the respective pathogen, its subtypes, and other family members. Currently GTD contains 58 drug targets for 
four pathogens. Shortly, drug targets for six more pathogens will be listed.  
 
Availability:  GTD is available at IIOAB website http://www.iioab.webs.com/GTD.htm. It can also be accessed at http://www.iioab-
dgd.webs.com. GTD is free for academic research and non-commercial use only. Commercial use is strictly prohibited without prior permission 
from IIOAB.   
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Background: 
Infectious diseases caused by various pathogenic bacteria are 
considered to be a major public health problem globally. Several 
pathogens have been reported to challenge the existing treatment 
regime by developing drug resistance and in several cases effective 
vaccines are yet to be developed.  Although, researches are going on to 
develop effective drugs and vaccines, the efforts are not yet successful 
due to the dynamic adaptability, frequent phase and antigenic 
modifications, variations in major virulence factors, and adoptive 
mutations. The advent of several microbial complete genome 
sequences along with development of various bioinformatics tools, 
made it faceable for in silico analysis of the genomes and subsequent 
drug discovery against deadly human pathogen. To date, NCBI 
genome database has listed approximately 2491 fully sequenced 
microbial genomes including pathogenic bacteria [1]  and 
computational approaches based on subtractive genomics have 
successfully been used to identify drug targets in many pathogenic 
bacteria [2, 3, 4]. However, structured data for genomic drug targets 
for any human pathogen do not exist [4]. Therefore, we developed a 
Genomic Target Database (GTD) to provide putative genomic drug 
targets categorized into pathogen specific unique metabolic pathways, 
host-pathogen common metabolic pathways, and membrane/surface 
localized drug targets for ten most common human pathogenic 
bacteria. It is hoped that GTD will serve as a readily available resource 
for both drug and vaccine development for the respective pathogen, its 
serotypes, family members, and pathogens containing homologous 
sequences of these drug targets.  
 
Methodology: 
Data collection: 
Available drug target data have been collected from various literature 
sources viz. PubMed [1], ScienceDirect [5], Google Scholar [6] etc. 
Pathogens, for which no data are available, were identified using 
subtractive genomics approaches as described elsewhere by Saharkar 
et al. (2004) [2]. These are based on the assumption that an essential 
survival gene of a given pathogen that is non-homologous to human 
host is a candidate drug target [7, 8]. 
.  
Identification of genomic drug targets: 
Complete genome and proteome sequences of selected pathogens from 
NCBI [1], BLAST tools, and databases such as Database of Essential 
Genes (DEG) [9] (http://tubic.tju.edu.cn/deg) and Kyoto Encyclopedia 
of Genes and Genomes (KEGG) [10] pathway database were used to 
identify putative drug targets. Each functional gene and corresponding 
protein sequence of the bacteria were subjected to standard BLAST-X 
and BLAST-P respectively against DEG. Pathogen homologs that 
showed significant hits against DEG listed essential genes were 
selected as putative essential genes for the pathogen under 
consideration based on the BLAST-P scores [cut off values for bit 
score (>100), E-value (<E-10), and percentage of identity at amino 
acid level (>35%)]. Genes encoding for <100 amino acids length were 
purged out. Each identified essential gene and corresponding protein 
sequence of the pathogen were analyzed for sequence homology with 
human genome using standard human BLAST-X and BLAST-P in 
NCBI server. Non-homologous essential genes considered as putative 
drug targets were selected based on the selection criteria that a drug 
target should not show any similarity with any human sequence.  The 
function and sub-cellular localization of each drug target was analyzed 
with Swiss-prot protein database [11] and by using sub-cellular 
localization prediction tools, CELLO [12], PSORTb [13], PSLpred 
[14], and SOSUI-GramN [15]. The KEGG database [10] was used for 
comparative pathway analysis and to identify proteins/enzymes that 
are involved in host-pathogen common and pathogen specific unique 
pathways.  Targets were listed according to the pathways where they 
are involved. The membrane or surface proteins (candidate vaccine 
targets) were grouped separately. 
 
Features, design, and contents of GTD: 
The GTD is a HTML based database and is represented in table 
format. The screenshot of the database is shown in Figure 1. For each 
genome, four pages are there. The first page contains the brief 
description of the pathogen, its taxonomy, virulence, and genome 
information etc. At the end of this page, three links (Drug targets in 
pathogen specific unique metabolic pathways, Drug targets in host-Bioinformation                                open access 
www.bioinformation.net                                                                                  Database 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 4(1): 50-51 (2009)    © 2009 Biomedical Informatics 
 
51
pathogen common metabolic pathways, and Membrane and surface 
localized drug targets) are given. Each corresponding link page 
contains list of identified gene/protein targets for that particular 
category. At the top of this page pathogen specific links to the main 
genome project, other publicly available DBs, search option, pathway 
links, and various BLASTs are given for subtractive genomics 
analysis. Below that literature references are mentioned (if available) 
for corresponding drug targets. Each entry in GTD is a potential drug 
target for the corresponding pathogen and links are provided for their 
various properties and other publicly accessible databases. In silico 
predicted sub-cellular localization is denoted as (P). Two separate 
pages have been allotted that contains downloadable data of GTD and 
links to various resources for drug and vaccine designing.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Figure 1: Screenshot image of Genomic Target Database (GTD) 
 
Data statistics and future development: 
The objective to develop GTD is to list out drug targets of 10 most 
common human pathogenic bacteria. Currently GTD contains 58 drug 
targets for four pathogens.  There are targets, specific to unique 
metabolic pathways in Burkholderia pseudomallei K96243 (27), 
Aeromonas hydrophila ATCC 7966 (18), and Vibrio cholerae (3). Ten 
membrane/surface localized drug targets have been listed for 
Helicobacter pylori. Listing of targets for other pathogens is in 
progress. 
 
Utility: 
(1) The GTD is designed to provide a readily available resource of 
putative genomic drug targets in most common human pathogenic 
bacteria. (2) All listed targets in GTD are essential genes for the 
pathogen. Therefore, GTD will help in designing mutagenesis study to 
validate essential genes of the organism. (3) The data can be used for 
both the drug and vaccine development for the respective pathogen, its 
sub-types, family members, and other similar species. (4) Screening of 
functional inhibitors against these listed targets may also result in 
discovery of novel therapeutic compounds that can be effective against 
antibiotic resistant strains.  
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